Elizabeth Hamilton

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Human cytomegalovirus and risk of incident cardiovascular disease in UK Biobank

T. Littlejohns, A. Mentzer, Elizabeth Hamilton, 2021 .

Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial.

James R. Stoddard, James E. Cartwright, Arun M Bhaskaran, 2022, Lancet.

Cancer Therapy : Clinical The Novel Expanded Porphyrin , Motexafin Gadolinium , Combined with [ 90 Y ] Ibritumomab Tiuxetan for Relapsed / Refractory Non-Hodgkin ' s Lymphoma : Preclinical Findings and Results of a Phase I Trial

L. Gordon, J. Winter, A. Evens, 2009 .

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma

J. Winter, Elizabeth Hamilton, B. Pro, 2022, British journal of haematology.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

L. Gordon, J. Winter, A. Evens, 2009, Clinical Cancer Research.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.